JNJ Stock Surges on IMAAVY Label Expansion and CAPLYTA Sales Growth

Johnson & Johnson's (NYSE:JNJ) stock has seen significant growth due to various factors. Recently, the company announced the expansion of its IMAAVY label, which is a treatment for bipolar depression. This move is expected to boost sales and contribute to the company's overall revenue.

The company also reported strong sales figures for CAPLYTA, another medication used to treat depression. Analysts believe that this growth will continue in the coming months, driven by the increasing demand for mental health treatments.

No specific target price was mentioned in the source, but analysts are optimistic about Johnson & Johnson's stock performance. They highlight the company's diversified portfolio and strong sales figures as key factors driving its success.